Imperial College London
Alternate

ProfessorRobinShattock

Faculty of Medicine, Department of Infectious Disease

Chair in Mucosal Infection and Immunity
 
 
 
//

Contact

 

+44 (0)20 7594 5206r.shattock

 
 
//

Location

 

453Wright Fleming WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kis:2019:10.1002/biot.201800376,
author = {Kis, Z and Shattock, R and Shah, N and Kontoravdi, K},
doi = {10.1002/biot.201800376},
journal = {Biotechnology Journal},
title = {Emerging technologies for low-cost, rapid vaccine manufacture},
url = {http://dx.doi.org/10.1002/biot.201800376},
volume = {14},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - To stop the spread of future epidemics and meet infant vaccination demands in low and middleincome countries, flexible, rapid and lowcost vaccine development and manufacturing technologies are required. Vaccine development platform technologies that can produce a wide range of vaccines are emerging, including: a) humanized, highyield yeast recombinant protein vaccines; b) insect cellbaculovirus ADDomer vaccines; c) Generalized Modules for Membrane Antigens (GMMA) vaccines; d) RNA vaccines. Herein, existing and future platforms are assessed in terms of addressing challenges of scale, cost, and responsiveness. To assess the risk and feasibility of the four emerging platforms, the following six metrics are applied: 1) technology readiness; 2) technological complexity; 3) ease of scaleup; 4) flexibility for the manufacturing of a wide range of vaccines; 5) thermostability of the vaccine product at tropical ambient temperatures; and 6) speed of response from threat identification to vaccine deployment. The assessment indicated that technologies in the order of increasing feasibility and decreasing risk are the yeast platform, ADDomer platform, followed by RNA and GMMA platforms. The comparative strengths and weaknesses of each technology are discussed in detail, illustrating the associated development and manufacturing needs and priorities.
AU  - Kis,Z
AU  - Shattock,R
AU  - Shah,N
AU  - Kontoravdi,K
DO  - 10.1002/biot.201800376
PY  - 2019///
SN  - 1860-6768
TI  - Emerging technologies for low-cost, rapid vaccine manufacture
T2  - Biotechnology Journal
UR  - http://dx.doi.org/10.1002/biot.201800376
UR  - http://hdl.handle.net/10044/1/65963
VL  - 14
ER  -
Download